Drug Profile
Belzupacap sarotalocan - Aura Biosciences/National Cancer Institute
Alternative Names: AU 011; Bel-sar; Belzupacap serotalocan; Light-activated AU-011Latest Information Update: 11 Dec 2023
Price :
$50
*
At a glance
- Originator Aura Biosciences; National Cancer Institute (USA)
- Developer Aura Biosciences
- Class Antineoplastics; Drug conjugates; Immunotherapies; Phthalocyanines; Viral proteins
- Mechanism of Action Cell death stimulants; Photosensitisers; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Uveal melanoma
- Phase I Bladder cancer
- Preclinical Solid tumours
Most Recent Events
- 07 Dec 2023 Phase-III clinical trials in Uveal melanoma (First-line therapy, Early-stage disease) in USA (Intraocular)
- 06 Nov 2023 Aura Biosciences plans to submit BLA for belzupacap sarotalocan for Uveal melanoma
- 06 Nov 2023 Aura Biosciences receives agreement from the US FDA under an Special Protocol Assessment (SPA) for the design and planned analysis of the phase III Compass trial for Uveal melanoma